A RIP1 con­tender fails to make the cut at GSK af­ter a fast fiz­zle in pan­cre­at­ic can­cer

Well, that didn’t last long.

Just months af­ter Glax­o­SmithK­line jumped in­to a clin­i­cal pro­gram for its RIP1 ki­nase in­hibitor GSK095 for pan­cre­at­ic can­cer, the pro­gram has been ter­mi­nat­ed.

There’s no ex­pla­na­tion in the Q3 out­line for what went wrong here be­yond a note on port­fo­lio pri­or­i­ti­za­tion, but the drug clear­ly didn’t live up to some ear­ly en­thu­si­asm in GSK’s in­creas­ing­ly dom­i­nant on­col­o­gy group un­der R&D chief Hal Bar­ron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER